Influenza vaccine for cardiovascular risk reduction

Hospital Pharmacy

Volumn 48, Issue 10, 2013, Pages 813-817

  Howard, Patricia ^a   Kleoppel, James ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; RAMIPRIL; TELMISARTAN;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INFLUENZA; INFLUENZA VACCINATION; RISK REDUCTION; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION;

EID: 84887439716     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4810-813     Document Type: Article

References (25)

1. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44-164.
2. Go AS, Mozaffarian D, Roger VL, et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation. 2013;127:e6-e245. http://my.americanheart.org/ statements. Accessed August 22, 2013.
3. DavisMM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: A science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006;114(14):1549-1553.
4. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis. 1987;136(3):550-555.
5. Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care. 2000;23:95-108.
6. Eickhoff TC, Sherman IL, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA. 1961;176(9):776-782.
7. Housworth J, Langmuir AD. Excessmortality from epidemic influenza, 1957-1966. Am J Epidemiol. 1974;100(1):40-48.
8. Reichert TA, Simonsen L, Sharma A, et al. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol. 2004;160(5):492-502.
9. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: A systematic review. Lancet Infect Dis. 2009;9(10):601-610.
10. Loomba RS, Aggarwal S, Shah PH, Arora RR. Influenza vaccination and cardiovascular morbidity and mortality: Analysis of 292,383 patients. J Cardiovasc Pharmacol Ther. 2012;17:277-283.
11. Johnstone J, Loeb M, Koon TK, et al. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation. 2012;126:27-86.
12. Teo K, Yusuf S, Sleight P, et al; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (ONTARGET/TRANSCENT) trials. Am Heart J. 2004;148:52-61.
13. ONTARGET Investigators, Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
14. TRANSCEND Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomized controlled trial. Lancet. 2008;372:1174-1183.
15. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J. 2004;25:25-31.
16. Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) registry. Tex Heart Inst J. 2004;31:28-32.
17. MacIntyre CR, Heywood AE, Kovoor P et al. Ischaemic heart disease, influenza and influenza vaccination: A prospective case control study [published online ahead of print August 22, 2013]. Heart. http://heart.bmj.com/search? fulltext5influenza&submit5yesx50y50. Accessed August 28, 2013.
18. Gurevich VS, Pleskov VM, Levaya MV. Autoimmune nature of influenza atherogenicity. Ann N Y Acad Sci. 2005; 1050(27):410-416.
19. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation. 2001;103(18):2283-2288.
20. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002;106(9):1127-1132.
21. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: A new opportunity for prevention and the need for further studies. Circulation. 2003; 108(22):2730-2736.
22. Naghavi M, Wyde P, Litovsky S, et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation. 2003;107(5):762-768.
23. Centers for Disease Control and Prevention (CDC). Additional information about vaccination of specific populations. Influenza prevention and control recommendations. http://www.cdc.gov/flu/professionals/acip/specificpopulations. htm. Accessed August 28, 2013.
24. Healthy People 2020. Immunization and infectious diseases. http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx? topicId523. Accessed August 26, 2013.
25. Centers for Disease Control and Prevention (CDC). Summary recommendations: Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices-(ACIP)- United States, 2013-14. http://www.cdc.gov/flu/professionals/acip/2013- summaryrecommendations. htm. Accessed August 25, 2013.